Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leuk...( SEATTLE and ORLANDO Fla. June 1 /- Tr...),Health

SEATTLE and ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the presentation of encouraging Phase 1 safety and efficacy results following administration of low doses of TRU-016 in heavily pre-treated patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company's proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Abstract 3017: A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)), in Relapsed and Refractory CLL -- Early Promising Clinical Activity

The clinical data presented at the American Society of Clinical Oncology (ASCO) are preliminary results from an ongoing Phase 1 / 2 clinical trial (#16007) of TRU-016 for the treatment of CLL and small lymphocytic leukemia (SLL). The objectives of the Phase 1 TRU-016 CLL study were to define safety and tolerability, identify a maximum tolerated dose, evaluate pharmacology and pharmacodynamics, and assess preliminary clinical activity. Patients received either one dose weekly for four weeks, or three doses the first week followed by three additional weekly doses. Patients were also able to receive up to two additional cycles if clinical benefit was observed.

At the time of the presentation, data were available for 26 patients enrolled in the Phase 1 dose escalation trial, all of whom had received an average of 6.5 prior treatments, including at least one fludarabine-containing regimen. All patients had also previously received rituximab or other anti-CD20 therapies an average of three times, either as a single agent
'/>"/>